PanCareSurPass Project HL7 FHIR Implementation Guide
0.2.0 - CI Build 150

PanCareSurPass Project HL7 FHIR Implementation Guide, published by PanCareSurPass Project. This guide is not an authorized publication; it is the continuous build for version 0.2.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/pcsp/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 PanCareSurPass FHIR IG - Home Page
... 2 Logical Models
... 3 Sequence diagrams
... 4 Collaboration diagrams
... 5 Profiles
... 6 Terminology
... 7 Extensions
... 8 Examples
... 9 Questionnaire
... 10 Useful Downloads
... 11 IG Change History
... 12 Artifacts Summary
.... 12.1 SurPass V2.0
.... 12.2 Bundle: Survivor Passport
.... 12.3 Care Plan
.... 12.4 Chemotherapy
.... 12.5 Diagnosis
.... 12.6 Front Line Treatment
.... 12.7 Major Surgery
.... 12.8 Metadata FSE Italy
.... 12.9 Other info and relevant events
.... 12.10 Progression-Relapse after FLT
.... 12.11 Progression-Relapse during FLT
.... 12.12 Radiotherapy
.... 12.13 Stem Cell Transplantation
.... 12.14 Subject of care
.... 12.15 Treatment Summary
.... 12.16 FollowupSurPass
..... 12.16.1 ValueSet
..... 12.16.2 ValueSet
.... 12.17 BiologicallyDerivedProduct: Stem Cell
.... 12.18 CarePlan: PCSP-generated plan
.... 12.19 Composition: Survivor Passport
.... 12.20 Condition: GvHD
.... 12.21 Condition: Metastatic Cancer
.... 12.22 Condition: Others
.... 12.23 Condition: Primary Cancer
.... 12.24 Condition: Severe Toxicity
.... 12.25 DocumentReference: PCSP
.... 12.26 Encounter: Treatment Center
.... 12.27 Location: PCSP
.... 12.28 MedicationAdministration: Chemotherapy
.... 12.29 MedicationStatement: Chemotherapy
.... 12.30 Observation: Blood type/RH
.... 12.31 Observation: Cancer Stage Group
.... 12.32 Observation: Chemotherapy Cumulative Dose
.... 12.33 Observation: Diagnosis details
.... 12.34 Observation: Hereditary Predisposition
.... 12.35 Observation: Radiotherapy Total Dose PCSP
.... 12.36 Observation: Risk Factor
.... 12.37 Observation: TNM Distant Metastases Category
.... 12.38 Observation: TNM Primary Tumor Category
.... 12.39 Observation: TNM Regional Nodes Category
.... 12.40 Organization: Primary Treatment Center / Center of diagnosis
.... 12.41 Patient: PCSP
.... 12.42 PlanDefinition: Front Line Treatment
.... 12.43 Procedure: Catheter
.... 12.44 Procedure: Cryopreservation
.... 12.45 Procedure: Front Line Treatment
.... 12.46 Procedure: Other Treatments
.... 12.47 Procedure: Radiotherapy
.... 12.48 Procedure: Radiotherapy Boost
.... 12.49 Procedure: Radiotherapy Shielding
.... 12.50 Procedure: SCT Prophylaxis
.... 12.51 Procedure: Stem Cell Transplantation
.... 12.52 Procedure: Surgery
.... 12.53 Procedure: Transfusion other infos
.... 12.54 Act Location
.... 12.55 Annotation Type
.... 12.56 Body Location Qualifier
.... 12.57 Condition related to resource
.... 12.58 Laterality Qualifier
.... 12.59 Not affected Organ
.... 12.60 Performed Timing
.... 12.61 Previous Status
.... 12.62 Procedure Used Reference
.... 12.63 Radiotherapy Energy or Isotope
.... 12.64 Randomization arm for trial
.... 12.65 Relapse Type
.... 12.66 Resource related information
.... 12.67 Sacrified organ
.... 12.68 Stem Cell Donor Type
.... 12.69 Stem Cell Source Type
.... 12.70 Active or resolved Condition
.... 12.71 Acute Gvhd Grade
.... 12.72 Affected Organs (surgery)
.... 12.73 Amputation Surgical Procedure Type
.... 12.74 Annotation type
.... 12.75 Antineoplastic and immunostimulating agents
.... 12.76 Before/after procedure
.... 12.77 Body Location Qualifier Value Set
.... 12.78 Body Location Qualifier Value Set
.... 12.79 Brachytherapy Type
.... 12.80 Calculated|Estimated
.... 12.81 Cancer Staging System Value Set
.... 12.82 Chemotherapy cumulative dose units
.... 12.83 Chronic Gvhd condition
.... 12.84 Colostomy Surgical Procedure Type
.... 12.85 Conditions at risk
.... 12.86 Conditions: follow up
.... 12.87 Document Type
.... 12.88 FLT Plan Type
.... 12.89 Gastrostomy Surgical Procedure Type
.... 12.90 Grade: follow up
.... 12.91 Gvhd condition
.... 12.92 Hereditary Predispositions (ICD10)
.... 12.93 Hereditary Predispositions (Orphacode)
.... 12.94 Hereditary Predispositions or Disease
.... 12.95 ICCC-3
.... 12.96 ICD-O-3 Morphology
.... 12.97 ICD-O-3 Topography
.... 12.98 Laterality Qualifier Value Set
.... 12.99 Morphologically abnormal structure
.... 12.100 Not Applicable|Unknown
.... 12.101 Not Performed|Unknown
.... 12.102 Observation Codes for Distant Metastases Category
.... 12.103 Observation Codes for Primary Tumor Category
.... 12.104 Observation Codes for Regional Node Category
.... 12.105 Observation Codes for Stage Group Category
.... 12.106 Other Infors Condition
.... 12.107 Other/Unknown/Text
.... 12.108 Prosthesis Type
.... 12.109 Prosthetic Surgical Procedure Type
.... 12.110 Radiotherapy Device Type
.... 12.111 Radiotherapy Dose Type
.... 12.112 Radiotherapy dose units
.... 12.113 Radiotherapy Isotopes
.... 12.114 Radiotherapy sites
.... 12.115 Radiotherapy Type
.... 12.116 Recommendations
.... 12.117 Relapse type (Local/Distant/Combined)
.... 12.118 Risk Factors
.... 12.119 Route of administration
.... 12.120 Sacrified Organs (surgery)
.... 12.121 SCT Prophylaxis Cathegory
.... 12.122 SCT Prophylaxis Type
.... 12.123 Shunt Procedure Type
.... 12.124 Stage Group Value Set
.... 12.125 Stem Cell Donor type
.... 12.126 Stem Cell Source type
.... 12.127 Stem Cell Transplantation type
.... 12.128 Surgical Actions
.... 12.129 Surgical Procedure Type
.... 12.130 TNM Distant Metastases Category Value Set
.... 12.131 TNM Primary Tumor Category Value Set
.... 12.132 TNM Regional Nodes Category Value Set
.... 12.133 Toxicity Severity
.... 12.134 Unknown|Other
.... 12.135 Conditions
.... 12.136 International Classification of Childhood Cancer, Third Edition
.... 12.137 International Classification of Diseases for Oncology, Third Edition
.... 12.138 OrphaNet
.... 12.139 PCSP Code System
.... 12.140 PCSP Conditions at risk
.... 12.141 PCSP Recommendations
.... 12.142 Radiotherapy sites
.... 12.143 Risk Factors
.... 12.144 Austria - Bundle: Example of a Childhood Cancer Survivor Passport
.... 12.145 Cineca - Clinical Protocol
.... 12.146 Cineca - Patient: Sample of Patient (Rossi)
.... 12.147 Hulafe - Bundle: Example of a Childhood Cancer Survivor Passport
.... 12.148 Hulafe - CarePlan: Follow-up Recommendations
.... 12.149 Hulafe - Condition: Primary Diagnosis
.... 12.150 Hulafe - DocumentReference: Preliminary SurPass
.... 12.151 Hulafe - Encounter: Primary Diagnosis
.... 12.152 Hulafe - Location: Chemotherapy
.... 12.153 Hulafe - MedicationAdministration: Chemotherapy Ciclofosfamide
.... 12.154 Hulafe - MedicationAdministration: Chemotherapy Citarabina
.... 12.155 Hulafe - MedicationAdministration: Chemotherapy Metotrexato
.... 12.156 Hulafe - MedicationAdministration: Chemotherapy Vincristina
.... 12.157 Hulafe - MedicationStatement: Chemotherapy Corticosteroids
.... 12.158 Hulafe - Observation: Chemotherapy Ciclofosfamide Cumulative Dose
.... 12.159 Hulafe - Observation: Chemotherapy Citarabina Cumulative Dose
.... 12.160 Hulafe - Observation: Chemotherapy Metotrexato Cumulative Dose
.... 12.161 Hulafe - Observation: Chemotherapy Vincristina Cumulative Dose
.... 12.162 Hulafe - Observation: Risk Factor Anthracyclines
.... 12.163 Hulafe - Observation: Risk Factor RT breasts
.... 12.164 Hulafe - Observation: Risk Factor RT heart
.... 12.165 Hulafe - Observation: Risk Factor RT thyroid gland
.... 12.166 Hulafe - Organization: Primary Diagnosis
.... 12.167 Hulafe - Patient: Sample of demographics data
.... 12.168 Hulafe - Patient: Sample of Patient (Basoa Mancebo)
.... 12.169 Mainz - BiologicallyDerivedProduct: Stem Cell Transplantation (Zeisig)
.... 12.170 Mainz - Condition: complete metastatic site Condition example (TBC) (Zeisig)
.... 12.171 Mainz - Condition: complete Primary Cancer Condition example (TBC) (Zeisig)
.... 12.172 Mainz - Condition: Primary Cancer (Fischer)
.... 12.173 Mainz - Encounter: Primary Cancer (Fischer)
.... 12.174 Mainz - Encounter: Primary Cancer (Zeisig)
.... 12.175 Mainz - Location: Stem Cell Transplantation (Zeisig)
.... 12.176 Mainz - Observation: Blood type/RH before the SCT (Zeisig)
.... 12.177 Mainz - Observation: Primary Cancer (Zeisig)
.... 12.178 Mainz - Observation: Radiotherapy Total Dose (Zeisig)
.... 12.179 Mainz - Patient: Sample of Patient (Fischer)
.... 12.180 Mainz - Patient: Sample of Patient (Zeisig)
.... 12.181 Mainz - Procedure: Radiotherapy (Zeisig)
.... 12.182 Mainz - Procedure: Stem Cell Transplantation (Zeisig)
.... 12.183 Mainz - Procedure: Transfusion (Zeisig)
.... 12.184 Vulsk - Patient: Sample of Patient (Jonaitė)